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The monoclonal antibody 791T/36, prepared against a human osteogenic sarcoma cell line, 791T, reacts 
with a variety of human tumours and also mitogen-stimulated PBMN cells. The target antigen as expressed 
upon 791T cells is a monomeric plasma membrane-associated glycoprotein with an apparent M, of 72000. 
By quantitative flow cytofluorimetry, approx. lo5 antibody molecules bound per cell to T-lymphoblasts 
induced with PHA or Con A, whereas only a few thousand antibody molecules bound per cell to 
unstimulated cells, so that the antigen may be classified as a lymphocyte activation antigen. On 
lymphoblasts, the 7913/36 again reacted with a protein with an apparent M, of 72000. This antigen 
therefore has a dual role as a tumour marker and lymphocyte activation antigen which may be implicated 
in the regulation of cell proliferation. 
Human osteogenic sarcoma antigen 
1. INTRODUCTION 
The murine monoclonal antibody, 791T/36 
(IgG2b), originally prepared against the human 
osteogenic sarcoma cell line, 791T, reacts with a 
number of human tumour cell lines [l] and after 
radioiodination, localizes within tumours in pa- 
tients with a variety of malignancies, including 
cola-rectal tumours [2] and osteogenic sarcomas 
[3]. The antibody has also been employed as a 
vehicle for cytotoxic drugs for the development of 
new therapeutic agents showing selective cytotox- 
icity against tumour cells [4,5]. 
Biochemical analysis of the antigen defined by 
the 791T/36 antibody has been initiated with a 
Abbreviations: PHA, phytohaemagglutinin; PBMN 
cells, peripheral blood mononuclear cells; FCS, foetal 
calf serum; Con A, concanavalin A; NP40, Nonidet- 
P40; PAGE, polyacrylamide gel electrophoresis; FITC, 
fluorescein isothiocyanate; PMSF, phenylmethylsul- 
phony1 fluoride; WGA, wheat germ agglutinin 
Lymphocyte activation antigen 
view to elucidate the nature and characteristics of 
this cell surface molecule [6] and the recent 
demonstration that the antibody reacts with PHA- 
stimulated PBMN cells, but not unstimulated cells 
[7] offers additional opportunities for evaluating 
the functional significance of the expression of this 
antigen. This paper describes recent developments 
in parallel studies on the 791T/36 antibody defined 
antigen as expressed upon the osteogenic sarcoma 
cell line 791T and mitogen-stimulated T- 
lymphoblasts. 
2. MATERIALS AND METHODS 
2.1. Cells 
Human osteogenic sarcoma 791T cells were 
grown as monolayer cultures in Eagle’s minimum 
essential medium supplemented with 10% FCS. 
Cells were harvested following brief exposure to 
0.25% trypsin. 
PBMN cells were prepared from heparinized 
blood by discontinuous gradient centrifugation 
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upon Ficoll-Triosil (Lymphoprep, Flow Labora- 
tories, Irvine, Scotland). Stimulation with PHA 
(Wellcome Reagents, Beckenham, England) and 
Con A (Sigma, Poole) at final concentrations of 5 
and 10 pg/ml, respectively, was performed em- 
ploying culture conditions as in [7]. 
represents the signal acquired from 2228 molecules 
of fluorescein (to be published) so that with FITC- 
labelled antibody-treated cells the mean number of 
antibody molecules bound per cell may be 
calculated using the FITC : IgG molar ratio. 
2.2. Monoclonal antibody 
3. RESULTS AND DISCUSSION 
Hybridoma 791T/36 Clone 3 [I] provided the The antigen precipitated by the monoclonal an- 
source of antibody from in vitro cultures. An- tibody 791T/36 from detergent lysates of 1251- 
tibody was purified by affinity chromatography labelled 791T cells migrated in SDS-PAGE slab 
using Sepharose-protein A (Pharmacia, Uppsala) gels with an apparent M, of 72000 (fig.1, lane 1). 
171. Both reduced and non-reduced samples gave 
so that the antigen is a 
2.3. Radioimmunoprecipitation of 791 T/36 
defined antigens 
equivalent results 
1 
791T osteogenic sarcoma cells and PBMN cells 
cultured with and without PHA were surface 
labelled with “‘1 (Na1251, Amersham Interna- 
tional, England) by lactoperoxidase-catalysed 
radioiodination [8] using approx. 1 mCi 1251/107 
cells. Detergent (OSOro NP40, BDH) lysates were 
prepared and immunoprecipitated antigens were 
isolated following the sequential addition of an- 
tibody (10 ,ug) and Sepharose-protein A [6]. 
Analysis of antigens collected on antibody- 
Sepharose-protein A was performed by SDS- 
PAGE and autoradiography [6]. Enzymic treat- 
ment of radiolabelled immunoprecipitates with 
Clostridium perfringens neuraminidase, papain 
and chymotrypsin (each from Sigma) was per- 
formed as described in the text. 
72- 
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2.4. Flow cytofluorimetry 
Cells treated with FITC-labelled 791T/36 an- 
tibody [6] added at saturation were analysed by 
flow cytometry using an FACS IV cell sorter (Bec- 
ton Dickinson, Sunnyvale, CA). Excitation was at 
120 mW at 488 nm from an argon ion laser and 
fluorescence was collected via a 10 nm band-pass 
filter centred at 515 nm. Appropriate forward 
angle scatter gating was used to confine analysis to 
viable cells or subpopulations of viable cells. 
Linear amplification was used to quantify mean 
fluorescence intensity and fluorescence signals 
were also amplified logarithmically for direct com- 
parison of fluorescence intensity. The results were 
expressed as the channel number which cor- 
responded to the mean fluorescence intensity per 
cell. Each unit increase in the channel number 
Fig. 1. SDS-PAGE analysis of immune precipitates 
prepared by the addition of 791T/36 antibody and 
Sepharose-protein A to NP40 lysates of radiolabelled 
791T tumour cells. Lane 1, untreated immune 
precipitate; lane 2, immune precipitate treated with C. 
perfrhgens neuraminidase; lane 3, immune precipitate 
treated with papain. The positions of M marker 
proteins are indicated to the right of the gel. 
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monomeric cell surface protein. As shown in fig. 1, 
lane 1, the relatively broad band suggests that the 
antigen may be glycosylated since microhetero- 
geneity in the saccharide residues would account 
for this observation. When immunoprecipitates 
were treated with neuraminidase (which had been 
pretreated with 1 mM PMSF) at up to 30,ug en- 
zyme per immunoprecipitate, the apparent A4, was 
reduced to 55 000 (fig. 1, lane 2) indicative of exten- 
sive glycosylation, and since in repeated tests, 
microheterogeneity in the band of precipitated 
material was lost following neuraminidase treat- 
ment, this microheterogeneity was attributable to 
variations in sialic acid content. 
That the p72 antigen is glycosylated was con- 
firmed by metabolically labelling tumour cells with 
[3H]glucosamine and again precipitating a 72-kDa 
antigen. Furthermore, using immunoadsorbent- 
purified p72 antigen, the molecule bound strongly 
to WGA, although less to Con A and not to lentil 
lectin (to be published). 
Following treatment of immunoprecipitates with 
papain (5 pg/sample) a major 52-kDa polypeptide 
was generated (fig. 1, lane 3). This also contained 
sialic acid since neuraminidase treatment reduced 
the apparent Ad, to 50000. This fragment retained 
the epitope for the 791T/36 antibody. In com- 
parable tests with chymotrypsin, it was again only 
possible to generate a large 47-kDa polypeptide 
which was resistant to further proteolysis. The 
findings suggest that only a limited portion of the 
72-kDa glycoprotein antigen is susceptible to pro- 
teolysis the remainder being resistant to degrada- 
tion in spite of a large excess of enzyme over 
substrate. This may be attributable to the molecule 
being heavily glycosylated as inferred from the 
results of neuraminidase treatment. 
The 791T/36 monoclonal antibody also reacts 
with PBMN cells stimulated with the T-cell 
mitogen, PHA [7]. Fig.2 illustrates this by showing 
3-dimensional displays generated by the FACS IV 
cell sorter in analyses of the reaction of FITC- 
labelled antibody with PBMN cultured for 3 days 
with and without PHA (lower and upper, respec- 
tively). With PHA-stimulated cultures, a large pro- 
portion of cells exhibited high forward angle light 
scatter and these corresponded to T-lymphoblasts. 
This was confirmed by morphological examination 
of cells sorted on the basis of their light scatter pro- 
perties. Material with low light scatter near the 
Non- 
Stimulated 
PBMN 
Cells 
PHA- 
Stimulated 
PBMN 
Ceils 
Fig.2. FACS IV cell sorter analyses. Three-dimensional 
displays of non-stimulated PBMN cells (upper) and 
PBMN cells cultured with PHA for 3 days (lower). Cells 
were treated with FITC-labelled 791T/36 antibody 
added at saturation (1 pg antibody protein/lO’ cells). 
The displays show the distribution of cells as a function 
of their surface fluorescence (i.e., uptake of 
FITC-791T/36 antibody) and their light scatter which is 
a measure of cell size. 
origin (fig.2) represents non-viable cells and cell 
debris. The T-lymphoblasts in PHA-stimulated 
PBMN cell cultures exhibited increased fluores- 
cence and using the gating facilities on the FACS 
IV cell sorter, forward angle scatter gates were set 
around the T-lymphoblast subpopulation thus ex- 
cluding small lymphocytes. The number of anti- 
body molecules binding per lymphoblast was 
determined from the mean fluorescence of this 
subpopulation. As shown in table 1, T-lympho- 
blasts induced by PHA or Con A bound around 
10’ antibody molecules per cell compared with 
lymphocytes from non-cultured or cultured but 
non-stimulated PBMN cell preparations which 
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Table 1 
Binding of FITC-labelled 791T/36 antibody to mitogen-stimulated PBMN cells as assessed by quantitative flow 
cytofluorime~y 
Cell subpopulation analysed 
Small lymphocytes from non-stimulated PBMN cell 
preparations 
Lymphoblasts from PBMN cell preparations 
cultured with PHA for 3 days 
Lymphoblasts from PBMN cell preparations 
cultured with Con A for 3 days 
Percentage of cells 
in subpopulation 
analysed 
(mean f SD) 
93.4 it 3.8 
(n = 18) 
45.5 It 22.2 
(n = 17) 
60.6 f 12.0 
(n = 6) 
Number of FITC- 
79lT/36 antibody 
molecules binding/cell 
(x lo-‘) (mean + SD) 
GO.1 
(n = 18) 
1.1 + 0.4 
(n = 17) 
0.9 f 0.5 
(n = 6) 
72- 
50- 
449 
129 
The number of determinations (n) is given in parentheses 
1 2 3 bound, as far as could be accurately measured, on- 
ly a few thousand antibody molecules per cell. 
From these data, it may be concluded that the 
791T/36 antibody defines a T-cell activation an- 
tigen upon mitogen-stimulated l~phoblasts. To 
compare this antigen with that expressed upon 
tumour cells (which bind approx. lo6 antibody 
molecules per cell), radio-immunoprecipitation 
tests and SDS-PAGE analyses were performed us- 
ing stimulated and non-stimulated PBMN cells. As 
shown in fig.3 the 791T136 antibody precipitated a 
protein with an apparent M, of 72000 which was 
equivalent o that precipitated from tumour cells. 
While this p72 antigen is a useful marker for 
solid tumours in diagnostic studies [2,3] and for 
targeting drug-antibody conjugates [4,5], the find- 
-30 
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Fig.3. SDS-PAGE analysis of immune precipitates 
prepared by the addition of antibodies and Sepharose- 
protein A to NP40 lysates of radiolabelled PBMN cells 
which had been cultured with PHA for 3 days. The 
antibodies used were 791T/36 monoclonal antibody 
(lane 1), normal mouse IgG (lane 2) and W6132 mono- 
clonal antibody (lane 3). The latter antibody, added as 
a positive control, defines HLA-A, B, C (shared 
determinant) and as shown, precipitates the HLA heavy 
chain (44 kDa) and ,9z-microglobulin (12 kDa). The 
common band with an apparent M, of 50000 
corresponds to the heavy chain of cell surface IgG 
associated with B-cells in the PBMN cell, which is 
precipitated by Sepharose-protein A, The 791T/36 
antibody failed to precipitate any protein with an 
apparent i& of 72000 from freshly prepared PBMN cells 
or from PBMN cells cultured for 3 days in the absence 
of PHA. 
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ing that it also appears on T-lymphoblasts suggests 
that it may have a more important biological role. 
It is unlikely that the antigen is merely a marker of 
cellular proliferation per se since its expression has 
not yet been found to be elevated on PBMN cells 
from a small number of patients (22) with a variety 
of leukaemias and infectious mononucleosis (M.R. 
Price and T.E. Blecher, unpublished). These have 
included acute lymphoblastic leukaemias (T-cell, 
Null-cell, ALL-transformation in chronic myeloid 
leukaemia), prolymphocytic leukaemia, myelo- 
blastic leukaemias (primary, relapsed, and AML- 
transformation in myelosclerosis) and acute mye- 
lomonoblastic leukaemia. Negative results have 
also been obtained with the circulating lympho- 
cytes of chronic lymphocytic leukaemia, and the 
‘blood overspill’ abnormal cells of cases of non- 
Hodgkin’s lymphoma, myelomatosis and Walden- 
Strom’s macroglobulinaemia. In addition, the ab- 
normal mononuclear cells of 4 cases of Paul- 
Bunnell-positive infectious mononucleosis have 
also given negative results. Many of these cells are 
transformed or transforming T-lymphocytes. 
Other lymphocyte activation antigens have been 
identified as receptors for essential protein 
nutrients required to support growth of a rapidly 
expanding cell population (e.g., transferrin recep- 
tors [9]) or as receptors for polypeptide hormones 
such as interleukin-2 required for maintaining the 
clonal expansion of T-cells primed with antigen or 
mitogen [lo]. The present results emphasise the im- 
portance of defining the characteristics and func- 
tional role of the p72 antigen since the findings 
may have dual relevance to an understanding of 
growth in malignancy and to the regulation of lym- 
phocyte proliferation in response to mitogen or an- 
tigen stimulation and thus be implicated in con- 
trolling the tempo or magnitude of T-cell immune 
responses. 
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